T cell activation—the process by which these key immune defenders recognize threats and mobilize against them—depends on ...
ESLA READ THE FULL ESLA RESEARCH REPORT Initiating Coverage We are initiating coverage of Estrella Immunopharma (NASDAQ: ESLA ...
The world is experiencing a hidden epidemic with kidney disease. More than 850 million people worldwide have some form of ...
Pulmonary arterial hypertension, or PAH, is a rare and severe disease characterized by elevated blood pressure in the ...
Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial ...
Immunic (NASDAQ:IMUX) executives outlined their multiple sclerosis (MS) development strategy and commercial thinking for ...
Mycobacterium tuberculosis utilizes nucleomodulins to disrupt host inflammatory responses and lysosomal maturation, uncovering a novel strategy for immune evasion and intracellular survival.
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety ...
The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...
UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T ...
When a virus infects a bacterial cell, the viral genome is the first component to be fully injected into the cell, making it an ideal immune target. A bacterial enzyme anchored to the membrane ...
Working memory is a cognitive function that is essential for carrying out everyday activities and temporarily retaining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results